Generally safe and well tolerated in clinical trial experience

Incidence of adverse events similar to saline control and TAcs1

  • Most commonly reported treatment-emergent adverse events (≥1%) in clinical studies included randomized, double-blind, parallel-group, placebo- and/or active-controlled, and pharmacokinetic/pharmacodynamic studies with follow-up ranging from 6 to 24 weeks
Overall incidence of adverse events
Adverse events
*

Incidence in which the adverse event rate is higher for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) than saline control.

Injected knee incidence of adverse events

Radiographic changes vs saline control and TAcs1

  • Radiographic changes in a Phase 3, randomized, double-blind, parallel-group, placebo- and active-controlled study (N=484) among patients with baseline and Week 24 injected-knee radiographs
Radiographic evaluation
Adverse events

TAcs=triamcinolone acetonide crystalline suspension.